Literature DB >> 1595785

Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment.

F S Cowchock1, E A Reece, D Balaban, D W Branch, L Plouffe.   

Abstract

OBJECTIVE: We attempted to compare the use of low-dose heparin with a standard dose of 40 mg prednisone daily (both plus low-dose aspirin) for treatment of pregnant women with antiphospholipid antibody-associated recurrent fetal loss with respect to maternal and perinatal morbidity and efficacy in prevention of fetal death. STUDY
DESIGN: A multicenter randomized trial included 20 patients. Generalizability of results from randomized patients was evaluated by means of additional data from 13 women refusing and 12 women ineligible for randomization. Data from study groups were compared with Fisher's exact test, and generalizability was evaluated with a chi 2 test for trend.
RESULTS: Live birth rates were the same (75%) with either treatment, but "serious" maternal morbidity and the frequency of preterm delivery were significantly higher among women randomly assigned to prednisone (p = 0.02 vs p = 0.006). Preterm delivery among prednisone-treated women was usually associated with premature rupture of the membranes or preeclampsia. These results could be generalized to the other groups of women ascertained during the course of the study.
CONCLUSIONS: Low-dose heparin should be preferred to prednisone when treatment is indicated for high-risk pregnant women with antiphospholipid antibodies.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595785     DOI: 10.1016/0002-9378(92)91596-3

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  71 in total

Review 1.  Diagnosis and management of inherited and acquired thrombophilias.

Authors:  F A Spencer; R C Becker
Journal:  J Thromb Thrombolysis       Date:  1999-04       Impact factor: 2.300

Review 2.  Treatment of the antiphospholipid antibody syndrome: progress in the last five years?

Authors:  M Petri
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 3.  Asthma in pregnancy.

Authors:  C Nelson-Piercy
Journal:  Thorax       Date:  2001-04       Impact factor: 9.139

4.  How to treat women with antiphospholipid antibodies in pregnancy?

Authors:  R H Derksen; P G De Groot; H K Nieuwenhuis; G C Christiaens
Journal:  Ann Rheum Dis       Date:  2001-01       Impact factor: 19.103

Review 5.  Update on the management of the pregnant patient with antiphospholipid antibody.

Authors:  L R Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

6.  Heparin and aspirin versus aspirin alone for prevention of recurrent pregnancy loss.

Authors:  Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2010-02       Impact factor: 4.592

7.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

8.  Prednisone Pharmacokinetics During Pregnancy and Lactation.

Authors:  Rachel J Ryu; Thomas R Easterling; Steve N Caritis; Raman Venkataramanan; Jason G Umans; Mahmoud S Ahmed; Shannon Clark; Ira Kantrowitz-Gordon; Karen Hays; Brooke Bennett; Matthew T Honaker; Kenneth E Thummel; Danny D Shen; Mary F Hebert
Journal:  J Clin Pharmacol       Date:  2018-05-07       Impact factor: 3.126

Review 9.  Duration of anticoagulation treatment for thrombosis in APS: is it ever safe to stop?

Authors:  Sinthiya Punnialingam; Munther A Khamashta
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 10.  Treatment of inflammatory rheumatic disorders in pregnancy: what are the safest treatment options?

Authors:  M Ostensen; R Ramsey-Goldman
Journal:  Drug Saf       Date:  1998-11       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.